Compare Novartis AG (NVS) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs SMX Security Matters plc — how do they compare? Novartis AG trades at $143.53 (market cap $268.57B), while SMX Security Matters plc trades at $3.86 (market cap $4.13M). The key difference: Novartis AG is far larger — about 65029.1× SMX Security Matters plc's market cap, and Novartis AG pays a 3.31% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and SMX Security Matters plc for 21 Days on average.
| NVS | SMX | |
|---|---|---|
Market Cap | $268.57B | $4.13M |
Volume | 1,532,573 | 124,362 |
Sector | Health | Industrials |
52-Week High | $168.62 | $74.08K |
52-Week Low | $121.80 | $3.79 |
Typical Hold Time | 82 Days | 21 Days |
Enterprise Value | $309.89B | -$27.20M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
SMX trades at $3.90, up 2.9% today, but faces significant financial challenges with no revenue reported for 2025 and a net loss of $169.18 million. The stock shows bearish technical signals with moving averages indicating selling pressure, though oscillators suggest potential short-term momentum. Recent news highlights the company's focus on recycled plastic verification technology and growing media coverage from major outlets.
The outlook remains highly speculative given the absence of revenue and substantial losses. Investment opportunity hinges on successful commercialization of SMX's material verification platform, while risks include cash burn sustainability and intense competition in the circular economy space. Wall Street sentiment appears cautious due to the company's unproven business model.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
